Adventures in Discordance- HIV Testing

Similar documents
An Evaluation of Qualitative HIV-2 RNA Referral Testing

Clinical HIV-2 Viral Load Testing of a Large Population of HIV-2 Infected Individuals

Supplementary Online Content

Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018

Shared Service Success

Overview of HIV Testing Practices and Technology

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection

Diagnostic Tests for HIV

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Complicated viral infections

New HIV Tests and Algorithm: A change we can believe in

2018 HIV and HCV Diagnostic Testing Survey

HIV Testing Technology and the Latest Algorithm

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

Viral Hepatitis Diagnosis and Management

Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic

Technical Bulletin No. 104b

Diagnosis and Management of Acute HIV

Technical Bulletin No. 104a

The Latest in HIV Tests: What Do the Results Mean?

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation

A Successful HIV Testing Quality Assurance Program: New York State Experience

The Alphabet Soup of Viral Hepatitis Testing

Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance

Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis

Human Immunodeficiency Virus Serology

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

Trends in molecular diagnostics

HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention

HIV Diagnostic Testing

The Evolving Landscape of HIV Prevention and Diagnosis

1 st and 2 nd Generation EIA

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

High Rate of Missed HIV Infections in Individuals With Indeterminate or Negative HIV Western Blots Based on Current HIV Testing Algorithm in China

2006 HIV Diagnostics Survey

A Summary of Clinical Evidence

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

The Latest on HIV Testing. Dominika Seidman, MD MAS

Maximizing Cornea and Tissue Donation through Specimen Quality

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

2017 HIV AND HCV DIAGNOSTICS SURVEY REPORT

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Hepatitis C: Surveillance, Case Definition, and Investigation

Case Definition and Lab Tests

Arizona State Office of Rural Health Webinar Series

INTEGRATING HIV AND HCV TESTING

DIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS

The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care HIV Diagnostic Conference March 24, 2010

HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests

HEV Assay Development Update

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*

Obstetrics and HIV An Update. Jennifer Van Horn MD University of Utah

HIV Guideline Sakchai Dettrairat

NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM)

Negative Hepatitis C Reporting and Linkage to Care Outreach

Routine HIV Testing Community of Practice Session #2

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

Objectives. Seven days of separation. Clinical situation a transplant. The Donor COOMBS MD PHD 1. Laboratory Diagnosis & Monitoring of HIV Infection

A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery

Module 3: Overview of HIV Testing Technologies

OR: Steps you can take in the clinic to prevent HIV infections

HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES

NAT Screening of Blood Donations in NBC, TRCS

Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program

DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA

The ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013

HEPATITIS B NON-IMMEDIATE NOTIFICATION EPIDEMIOLOGY PROGRAM

TEST REQUEST INFORMATION- VIROLOGY

July Monthly Update, Quest Diagnostics Nichols Institute, Valencia

Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings

Hepatitis C January 26, 2018

Point-of-care HIV testing

2019 HIV DIAGNOSTICS CONFERENCE

Robert G. Gish MD UC San Diego

Zika virus: laboratory diagnosis

Diagnostics RDT / POC Technology for ZIKA related infections

HIV-2 Infection in Malaysia: Current situation and the use of in-house real-time reverse transcription PCR for HIV-2

Arbovirus Reports 2015

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence

VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory

Diagnostic Methods of HBV and HDV infections

Virology Proficiency Testing Program. Restricted Category Direct Antigen Detection

Mom Chandara, Msc, NIPH Team

Hepatitis C Best Practice Guidelines For Local Health Departments

MTN 009 Laboratory Logistics

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27

Clinical Education Initiative TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING. Bernard M.

Parvovirus B19 Mixed Titer Performance Panel PVP201

Rapid testing algorithm performance in a low prevalence environment: NJ

For information only: all participants in the graduated plan procedure. 7 January 2013

Transcription:

Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing

HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody immunoassay Updated January 2018 (+) (-) Negative for HIV-1 and HIV-2 antibodies and p24 antigen HIV-1/HIV-2 antibody differentiation immunoassay HIV-1 Positive HIV-1 (+) HIV-2 (-) HIV-1 Ab detected HIV-2 Positive HIV-1 (-) HIV-2 (+) HIV-2 Ab detected HIV Positive HIV-1 (+) HIV-2 (+) HIV Ab detected HIV Negative or HIV, HIV-1, HIV-2 Indeterminate HIV-1 (-) or Indeterminate & HIV-2 (-) Indeterminate HIV-1 NAT (+) indicates reactive test results (-) indicates negative test results NAT: nucleic acid test NAT (+) NAT (-) Acute HIV-1 Infection Negative for HIV-1

HIV Infection and Laboratory Markers HIV RNA (plasma) HIV p24 Ag HIV Antibody IgM IgG Eclipse 0 10 20 30 40 50 60 70 80 90 100 Days Since Infection Figure adapted from Delaney et al., CID 2017:64 and provided by M. Owen, NCHHSTP, CDC

NY State HIV Testing Provides HIV-1 NAT Testing for any clinical hospital within NYS Provides HIV-2 NAT and Viral Load for persons with HIV-2 in NYS Will also repeat algorithm upon request for a new case of HIV-2 as needed to ensure quality test results

Case 1: Misconceptions, Discordance and Reality Testing at Hospital Laboratory HIV-1/2 antigen/antibody immunoassay a Patient Details: From Ghana Previous Diagnosis of HIV-2 Reactive HIV-1/HIV-2 antibody differentiation immunoassay HIV Positive Untypable HIV-1 (+) HIV-2 (+) Positive for HIV-1 and HIV-2 Antibodies What additional testing/workup would you do? What was ordered: Hospital requested HIV-1 Viral Load in-house. Hospital sends sample to Wadsworth for HIV-2 Viral Load due to suspect case

Case 1: Misconceptions, Discordance and Reality Testing at Wadsworth HIV-1/2 antigen/antibody immunoassay a Reactive HIV-1/HIV-2 antibody differentiation immunoassay Any explanations? Any additional testing? HIV-1 Positive HIV-1 (+) HIV-2 (-) HIV-2 NAT Undetected

Case 1: Misconceptions, Discordance and Reality Summary of Testing Testing Performed at HIV Ag/Ab (s/co) Hospital Laboratory Reactive HIV Positive, Untypeable HIV-1/2 Ab Diff HIV-1 RNA Qual HIV-1 RNA Quant N/A Positive Wadsworth Reactive HIV-1 Positive N/A Not Detected Conclusion: HIV-1 Positive; Ab cross-reactivity HIV-1 positive bands:[hiv-1 gp41+, gp160+; HIV-2 gp36+] gp41 and gp36 are homologs with known cross-reactivity HIV-1 antibodies confirmed, HIV-2 antibodies never confirmed HIV-1 RNA detected HIV-2 RNA not detected

HIV-2: Information and Detection Endemic in West Africa; Very low prevalence in U.S. Majority of U.S. cases in Northeast, especially NYC which is home to many West African immigrants HIV-2 Abs may cross-react with HIV-1 Ags, but genomic sequence is <50% homologous to HIV-1 In the past, HIV-2 often misdiagnosed as HIV-1 by Western blot HIV-1/2 Ab differentiation test (step 2) accurately confirms HIV-2 antibodies But, can also produce HIV-2 indeterminate and HIV indeterminate results

HIV-2 NAT No HIV-2 NAT test kits available (qual or quant) HIV-1 NATs will not detect HIV-2 Wadsworth has HIV-2 RNA real-time PCR LDTs Qualitative LOD = 7 IU/mL Quantitative LLOQ = 41 IU/Ml Validated and approved by NYS Clinical Lab Evaluation Program (CLEP)

Case 2: But is this one HIV-2? Test Wadsworth BVL Result HIV Ag/Ab IA Reactive (s/co 467) HIV-1/2 Ab Diff HIV Positive, Untypable [HIV-1 31+, gp41+, gp160+; HIV-2 gp36+, gp140+] New patient from Burkina Faso Requested HIV-2 Viral Load (noted HIV-2 pos WB in 2011) NY called the hospital doctor: also reported a positive HIV-1 WB ~10 years ago.

HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody immunoassay Updated January 2018 (+) (-) Negative for HIV-1 and HIV-2 antibodies and p24 antigen HIV-1/HIV-2 antibody differentiation immunoassay HIV-1 Positive HIV-1 (+) HIV-2 (-) HIV-1 Ab detected HIV-2 Positive HIV-1 (-) HIV-2 (+) HIV-2 Ab detected HIV Positive HIV-1 (+) HIV-2 (+) HIV Ab detected HIV Negative or HIV, HIV-1, HIV-2 Indeterminate HIV-1 (-) or Indeterminate & HIV-2 (-) Indeterminate HIV-1 NAT (+) indicates reactive test results (-) indicates negative test results NAT: nucleic acid test NAT (+) NAT (-) Acute HIV-1 Infection Negative for HIV-1

Case 2: But is this one HIV-2? Test Wadsworth BVL Result HIV Ag/Ab IA Reactive (s/co 467) HIV-1/2 Ab Diff HIV-1 RNA Qual HIV-2 RNA Qual HIV-2 RNA Quant HIV Positive, Untypable [HIV-1 31+, gp41+, gp160+; HIV-2 gp36+, gp140+] Not detected Detected 3361 IU/mL Conclusion: HIV-2 Positive; Strong Ab cross-reactivity to HIV-1 Ags

Case 3: What at first appears simple HIV-1/2 antigen/antibody immunoassay Reactive Detection of Acute HIV-1 Infection HIV-1/HIV-2 antibody differentiation immunoassay HIV Negative HIV-1 (-) HIV-2 (-) But 2 weeks later a 2 nd sample from the same patient is submitted for testing HIV-1 NAT Detected

Case 3: What at first appears simple has gotten more complicated Sample HIV Ag/Ab (s/co) s/co <1: nonreactive, s/co > 1: reactive HIV-1/2 Ab Diff What is a potential explanation? What would you do next? HIV-1 RNA Qual Sample 1 Reactive (1.04) Nonreactive Detected *Very low signal New Sample Reactive (1.34) HIV-1 Indeterminate Not Detected

Case 3: What at first appears simple has gotten more complicated Sample HIV Ag/Ab (s/co) HIV-1/2 Ab Diff HIV-1 RNA Qual Sample 1 Reactive (1.04) Nonreactive Detected Sample 2 Nonreactive (0.93) N/A N/A (not tested at Wadsworth) Sample 3 Reactive (1.34) HIV-1 Indeterminate Not Detected s/co <1: nonreactive, s/co > 1: reactive Any additional guesses?

Case 3: What at first appears simple has gotten more complicated High-risk individual on PreP (pre-exposure prophylaxis) 3 specimens tested over 3-week period When first specimen came back positive, suspected the result was false-positive Second sample was negative but provider was still uncertain Worried about potential breakthrough infection Breakthrough infection is suspected, but person is still on PreP Serconversion may be delayed and virus detection impeded by ARVs

An Increasing Diagnostic Challenge As PreP use increases, this situation may arise more frequently Also ARV treatment of early/acute infection may delay Ab response Difficult to verify infection, if needed HIV-1 DNA PCR test may be needed in these cases no FDA-approved kits This sample sent to Quest for HIV-1 DNA PCR

More diagnostic tools needed PreP and ARV prophylaxis in HIV-exposed infants pose diagnostic challenges Viral suppression may impede RNA detection Naturally low RNA levels for HIV-2 can also leave doubt regarding status when RNA test is negative

Acknowledgements NYSDOH-Wadsworth Center Bloodborne Viruses Laboratory Monica Parker Tim Sullivan Linda Styer